Pharmala Biotech Holdings Inc. (CSE:MDMA)

Revenue by Segment

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
MDMA and MDXX Class Molecules	605.50K	1.04M	532.00K	78.07K
MDMA and MDXX Class Molecules Growth	-41.51%	94.60%	581.44%	-
Total	605.50K	1.04M	532.00K	78.07K
Total Growth	-41.51%	94.60%	581.44%	-

Revenue by Geography

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023
Canada	29.58K	69.96K	12.31K
Canada Growth	-57.72%	468.10%	-
United States	350.25K	32.38K	-
United States Growth	981.76%	-	-
Australia	225.67K	844.71K	420.34K
Australia Growth	-73.28%	100.96%	-
Unallocated	-	88.25K	-
Europe	-	-	99.35K
Total	605.50K	1.04M	532.00K
Total Growth	-41.51%	94.60%	-

Source: S&P Global Market Intelligence.